Dr. David Braun speaks with Dr. Katy Beckermann on a Nature publication on a neoantigen vaccine that has demonstrated the ability to generate antitumor immunity in RCC.
In this segment, they highlight the logistical and biological considerations that influenced the trial design, the complexities of manufacturing and regulatory approval, the critical role of a multidisciplinary team in antigen selection and peptide synthesis, and the remarkable commitment of patients who underwent extensive procedures to advance the science, all while emphasizing the potential of such vaccines in the minimal residual disease setting.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.